Dexcom rises as FDA clears use of its 15-day continuous glucose monitor

Shares of medical device maker Dexcom DXCM.O rise 8.6% to $72.60 premarket

Co says U.S. FDA has cleared its 15-day continuous glucose monitoring (CGM) device called Dexcom G7 15 Day for people over the age of 18 with diabetes in the United States

Co says the CGM lasts for 15.5 days and helps in "easier glucose management with fewer monthly sensors and reduced monthly waste"

Co's other G7 CGM lasts for up to 10 days, while its over-the-counter CGM Stelo also lasts for 15 days

Approval for co's 15-day CGM should provide momentum through 2025, brokerage William Blair had said in a note in February

Up to last close, stock had fallen 14.1% YTD